

10/516858

D112 Rec'd PCT/PTO 03 DEC 2004

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Express Mail Label No.: EV 282 741 418 US

Substitute for form 1449A/B/PTO				Complete If Known	
				Application Number	Not Yet Assigned 10/516,858
				Filing Date	Concurrently Herewith 7/21/05
				First Named Inventor	Bengt Hersløf
				Art Unit	AA 1743
				Examiner Name	Not Yet Assigned Maureen Wallenhorst
Sheet	1	of	1	Attorney Docket Number	C2432.0060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
mw	AA	US 5,626,869	05-06-1997	Nyqvist Hakan, et al.	
mw	AB	US-5,082,667	01-21-1992	Kurt G. Van Scoik	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		T ⁶
mw	BA	WO-92/05771-A1	04-16-1992	KABI PHARMACIA AB	
mw	BB	EP-0368247-A2	05-16-1990	TAKEDA CHEMICAL INDUSTRIES, LTD.	
mw	BC	WO-03/49721-A1	06-19-2003	COSMO S.P.A.	
mw	BD	WO-02/47663-A1	06-20-2002	F. HOFFMAN-LA ROCHE AG	
mw	BE	WO-01/91729-A1	12-06-2001	BASF AKTIENGESELLSCHAFT	
mw	BF	WO-93/19737-A1	10-14-1993	KABI PHARMACIA AB	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
mw	CA	European Journal of Pharmaceutical Sciences, Volume 1, 1994, L. Lohikangas et al.: "Relative contribution of phosphatidylcholine and monoglyceride to absorption enhancement of low molecular weight heparin (Fragmin) by a new lipid-based drug delivery system in monolayers of human intestinal epithelial Caco-2 cells and after rectal administration to rabbits"; pp. 307 - 312, abstract 3.1, 3.3, discussion			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Maureen Wallenhorst	Date Considered	11-8-05
--------------------	---------------------	-----------------	---------